Retension Pharmaceuticals Prices Upsized $45M IPO, Begins Nasdaq Trading
Retension Pharmaceuticals, Inc. (NASDAQ: RTSN) priced its upsized initial public offering at $45 million on October 14, 2026, and commenced trading on Nasdaq. A clinical-stage biotech focused on neurodegenerative diseases, the company will use proceeds for Phase II trials and CMC process development.
51CFO view：Biotech CFOs post-IPO must defend ASC 730 R&D capitalization policies, stage-based clinical trial accruals, and CMC cost allocation between inventory and R&D in first 10-Q — requiring FDA submission knowledge alongside SEC disclosure rigor to avoid comment letters.
Retension Pharmaceuticals, Inc. (NASDAQ: RTSN) priced its upsized initial public offering at $45 million on October 14, 2026, and commenced trading on Nasdaq. A clinical-stage biotech focused on neurodegenerative diseases, the company will use proceeds for Phase II trials and CMC process development.
Source：Google News · 美股 IPO
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →